Details for Patent: 10,961,190

✉ Email this page to a colleague

Which drugs does patent 10,961,190 protect, and when does it expire?

Patent 10,961,190 protects XERAVA and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 10,961,190

Title:	Crystalline forms of eravacycline
Abstract:	The invention relates to crystalline forms of the bis-HCI salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCI salt of a compound represented by Structural Formula 1. ##STR00001##
Inventor(s):	LaFrance; Danny (Natick, MA), Hogan; Philip C. (Brighton, MA), Liu; Yansheng (Winchester, MA), He; Minsheng (Andover, MA), Chen; Chi-Li (Newton, MA), Niu; John (Bedford, MA)
Assignee:	Tetraphase Pharmaceuticals, Inc. (Watertown, MA)
Application Number:	16/342,779
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 10,961,190

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tetraphase Pharms	XERAVA	eravacycline dihydrochloride	POWDER;INTRAVENOUS	211109-001	Aug 27, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y			⤷ Sign Up
Tetraphase Pharms	XERAVA	eravacycline dihydrochloride	POWDER;INTRAVENOUS	211109-002	Jun 3, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,961,190

PCT Information
PCT Filed	October 19, 2017	PCT Application Number:	PCT/US2017/057385
PCT Publication Date:	April 26, 2018	PCT Publication Number:	WO2018/075767

International Family Members for US Patent 10,961,190

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	110582486	⤷ Sign Up
China	117903083	⤷ Sign Up
Denmark	3529236	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.